| Medical and Health Sciences | Lifetime | 837 | FR 18 | 99.96 |
| Medical and Health Sciences | 2021-2025 | 861 | FR 28 | 99.80 |
| Dermatology | Lifetime | 7 | FR 1 | 99.91 |
| Oncology | Lifetime | 400 | FR 19 | 99.32 |
| Epidemiology | Lifetime | 812 | FR 31 | 98.91 |
| Immunology | Lifetime | 851 | FR 34 | 97.24 |
| Dermatology | 2021-2025 | 21 | FR 1 | 99.72 |
| Oncology | 2021-2025 | 290 | FR 18 | 97.37 |
| Acne and Rosacea Treatments and Effects | Lifetime | 1 | FR 1 | 99.90 |
| Skin Protection and Aging | Lifetime | 7 | FR 1 | 99.77 |
| Dermatology and Skin Diseases | Lifetime | 29 | FR 1 | 99.77 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 17 | FR 1 | 99.55 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 24 | FR 1 | 99.48 |
| melanin and skin pigmentation | Lifetime | 40 | FR 3 | 99.18 |
| Cutaneous Melanoma Detection and Management | Lifetime | 46 | FR 3 | 99.50 |
| CAR-T cell therapy research | Lifetime | 143 | FR 12 | 99.46 |
| Dermatologic Treatments and Research | Lifetime | 55 | FR 2 | 99.23 |
| Melanoma and MAPK Pathways | Lifetime | 59 | FR 5 | 99.31 |
| Dermatological diseases and infestations | Lifetime | 23 | FR 5 | 98.97 |
| Pharmacological Effects of Natural Compounds | Lifetime | 145 | FR 3 | 98.71 |
| Cancer and Skin Lesions | Lifetime | 87 | FR 3 | 98.94 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 349 | FR 30 | 99.17 |
| Nail Diseases and Treatments | Lifetime | 85 | FR 5 | 99.04 |
| Immunotherapy and Immune Responses | Lifetime | 463 | FR 18 | 99.23 |
| Vitamin C and Antioxidants Research | Lifetime | 181 | FR 6 | 97.39 |
| Hedgehog Signaling Pathway Studies | Lifetime | 207 | FR 9 | 96.72 |
| Contact Dermatitis and Allergies | Lifetime | 341 | FR 11 | 97.23 |
| Dermatological and COVID-19 studies | Lifetime | 93 | FR 6 | 94.16 |
| Polyomavirus and related diseases | Lifetime | 602 | FR 30 | 95.52 |
| vaccines and immunoinformatics approaches | Lifetime | 504 | FR 11 | 94.93 |
| Oral Health Pathology and Treatment | Lifetime | 607 | FR 10 | 95.17 |
| T-cell and Retrovirus Studies | Lifetime | 691 | FR 34 | 94.63 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 104 | FR 4 | 94.20 |
| Autoimmune Bullous Skin Diseases | Lifetime | 980 | FR 68 | 94.11 |
| Chemotherapy-related skin toxicity | Lifetime | 296 | FR 16 | 91.08 |
| Infectious Diseases and Mycology | Lifetime | 999 | FR 45 | 90.37 |
| Medical and Biological Ozone Research | Lifetime | 398 | FR 3 | 88.24 |
| Medicine and Dermatology Studies History | Lifetime | 443 | FR 12 | 88.19 |
| Genetic and rare skin diseases. | Lifetime | 877 | FR 42 | 85.05 |
| Drug-Induced Ocular Toxicity | Lifetime | 400 | FR 25 | 80.26 |
| Acne and Rosacea Treatments and Effects | 2021-2025 | 1 | FR 1 | 99.66 |
| Skin Protection and Aging | 2021-2025 | 4 | FR 2 | 99.44 |
| Dermatology and Skin Diseases | 2021-2025 | 65 | FR 2 | 99.01 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 36 | FR 1 | 97.39 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 71 | FR 2 | 97.51 |
| melanin and skin pigmentation | 2021-2025 | 39 | FR 5 | 95.91 |
| CAR-T cell therapy research | 2021-2025 | 853 | FR 35 | 95.17 |
| Immunotherapy and Immune Responses | 2021-2025 | 918 | FR 26 | 91.22 |
| Melanoma and MAPK Pathways | 2021-2025 | 136 | FR 9 | 92.93 |
| Dermatologic Treatments and Research | 2021-2025 | 230 | FR 7 | 90.79 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 126 | FR 8 | 79.48 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 162 | FR 2 | 80.91 |
| Cancer and Skin Lesions | 2021-2025 | 572 | FR 26 | 72.20 |
| Contact Dermatitis and Allergies | 2021-2025 | 700 | FR 30 | 73.97 |
| Vitamin C and Antioxidants Research | 2021-2025 | 690 | FR 6 | 59.51 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 527 | FR 11 | 61.13 |
| Chemotherapy-related skin toxicity | 2021-2025 | 600 | FR 19 | 45.52 |
